ADMA Biologics, Inc. (ADMA)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $2.04B
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 4, 2026
Profit #51 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 95.9% | 96.6% | 96.3% | 96.8% |
Growth #443 of 1484 companies
Payout #579 of 1484 companies
Safety #566 of 1484 companies
Price #268 of 1484 companies
